(2,4-二甲氧基-苯基)-乙酸酰胺 | 666175-56-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2,4-二甲氧基-苯基)-乙酸酰胺
• 英文名称: (2,4-dimethoxy-phenyl)-acetic acid amide
• 英文别名: (2,4-Dimethoxy-phenyl)-essigsaeure-amid；2-(2,4-Dimethoxyphenyl)acetamide
• CAS: 666175-56-0
• 化学式: C₁₀H₁₃NO₃
• mdl: MFCD11643416
• 分子量: 195.218
• InChiKey: IXJXZNQNXMXDPN-UHFFFAOYSA-N

物化性质

• 熔点：
  130-131 °C
• 沸点：
  384.3±32.0 °C(Predicted)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2,4-二甲氧基-苯基)-乙酸酰胺 在 三氯氧磷 作用下， 生成 2-(2,4-二甲氧基苯基)乙腈
  参考文献：
  名称：

  693.高铁白蛋白的合成

  摘要：

  DOI：

  10.1039/jr9530003454
• 作为产物：
  描述：

  (2,4-dimethoxy-phenyl)-acetyl chloride 在 六甲基二硅氮烷 作用下， 以 二氯甲烷 为溶剂， 生成 (2,4-二甲氧基-苯基)-乙酸酰胺
  参考文献：
  名称：

  Pd(OAc)2 催化芳基乙酰胺的内酯化反应，涉及 C-H 键的氧化

  摘要：

  含有喹啉-8-基甲胺作为导向基团的芳基乙酰胺与PhI(OAc)2在Pd(OAc)2作为催化剂存在下发生内酯化反应得到γ-内酯...

  DOI：

  10.1246/cl.150041

文献信息

• Enzymatic nitrile hydrolysis catalyzed by nitrilase ZmNIT2 from maize. An unprecedented β-hydroxy functionality enhanced amide formation
  作者：Chandrani Mukherjee、Dunming Zhu、Edward R. Biehl、Rajiv R. Parmar、Ling Hua

  DOI：10.1016/j.tet.2006.04.069

  日期：2006.6

  To explore the synthetic potential of nitrilase ZmNIT2 from maize, the substrate specificity of this nitrilase was studied with a diverse collection of nitriles. The nitrilase ZmNIT2 showed high activity for all the tested nitriles except benzonitrile, producing both acids and amides. For the hydrolysis of aliphatic, aromatic nitriles, phenylacetonitrile derivatives and dinitriles, carboxylic acids

  为了探索玉米中腈水解酶ZmNIT2的合成潜力，研究了该腈水解酶的底物特异性，并收集了多种腈。腈水解酶ZmNIT2对除苄腈以外的所有测试腈均显示高活性，同时生成酸和酰胺。对于脂族，芳族腈，苯乙腈衍生物和二腈的水解，羧酸是主要产物。出乎意料的是，发现酰胺是腈水解酶ZmNIT2催化的β-羟基腈水解的主要产物。酶-底物复杂中间体中羟基和氮之间的氢键不利于氨的损失和酰基-酶中间体的形成，后者进一步水解为酸，
• Pharmaceutical use of substituted amides
  申请人：Andersen Sune Henrik

  公开号：US20060111366A1

  公开（公告）日：2006-05-25

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文介绍了使用取代酰胺来调节11β-羟化甾体脱氢酶1型（11βHSD1）的活性以及将这些化合物用作制药组合物的方法。还介绍了一类新型的取代酰胺，它们在治疗中的应用、包含这些化合物的制药组合物以及它们在药物制剂制造中的应用。这些化合物是11βHSD1的调节剂，更具体地说是抑制剂，可用于治疗、预防和/或预防一系列需要降低活性糖皮质激素细胞内浓度的医学疾病。
• Amide Derivatives and Pharmaceutical Use Thereof
  申请人：Andersen Henrik Sune

  公开号：US20090264414A1

  公开（公告）日：2009-10-22

  The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代酰胺来调节11β-羟化类固醇脱氢酶1型（11βHSD1）活性以及这些化合物作为药物组分的用途。还描述了一类新型的取代酰胺，它们在治疗中的用途，包括含有这些化合物的药物组分以及它们在制造药物中的用途。这些化合物是调节剂，更具体地说是11βHSD1活性的抑制剂，可用于治疗、预防和/或预防一系列医学疾病，其中降低细胞内活性糖皮质激素的浓度是可取的。
• VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0620003A1

  公开（公告）日：1994-10-19

  A benzazepine compound represented by formulae (I) or (II) or a salt thereof, and a vasopressin antagonist or an oxytocin antagonist containing the above compound as the active ingredient.

  由式（I）或（II）代表的苯并氮杂卓化合物或其盐，以及含有上述化合物作为活性成分的血管加压素拮抗剂或催产素拮抗剂。
• Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
  申请人：NOVO NORDISK A/S

  公开号：EP1854487A2

  公开（公告）日：2007-11-14

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。